ANI Pharmaceuticals Inc
ANIP82.850USD
+0.020+0.02%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
1.86BMarket Cap
48.51P/E TTM
More Details of ANI Pharmaceuticals Inc Company
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals Inc Info
Ticker SymbolANIP
Company nameANI Pharmaceuticals Inc
IPO dateMay 04, 2000
CEOLalwani (Nikhil Suresh)
Number of employees897
Security typeOrdinary Share
Fiscal year-endMay 04
Address210 Main Street West
CityBAUDETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code56623
Phone12186343500
Websitehttps://www.anipharmaceuticals.com/
Ticker SymbolANIP
IPO dateMay 04, 2000
CEOLalwani (Nikhil Suresh)
Company Executives of ANI Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
-6.68%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Other
73.39%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Other
73.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.11%
Investment Advisor/Hedge Fund
23.24%
Hedge Fund
19.41%
Individual Investor
7.45%
Research Firm
6.42%
Private Equity
4.52%
Corporation
2.84%
Pension Fund
1.67%
Bank and Trust
1.33%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
2023Q3
378
15.97M
79.12%
+734.26K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.37M
10.64%
-68.37K
-2.80%
Jun 30, 2025
The Vanguard Group, Inc.
1.27M
5.71%
+95.32K
+8.09%
Jun 30, 2025
Meridian Venture Partners
1.01M
4.55%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
716.12K
3.21%
+1.55K
+0.22%
Jun 30, 2025
Esjay L.L.C,
632.62K
2.84%
-200.00K
-24.02%
Mar 14, 2025
Global Alpha Capital Management Ltd.
862.09K
3.87%
+126.50K
+17.20%
Jun 30, 2025
UBS Financial Services, Inc.
401.55K
1.8%
+137.16K
+51.88%
Jun 30, 2025
Citadel Advisors LLC
569.63K
2.56%
-153.70K
-21.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
553.89K
2.48%
-77.67K
-12.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
427.55K
1.92%
-2.08K
-0.48%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
View more
Invesco Pharmaceuticals ETF
Proportion2.63%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.63%
Innovator IBD Breakout Opportunities ETF
Proportion1.38%
Innovator IBD 50 Fund ETF
Proportion1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.98%
Invesco S&P SmallCap Health Care ETF
Proportion0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.92%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.67%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ANI Pharmaceuticals Inc?
The top five shareholders of ANI Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A. holds 2.37M shares, accounting for 10.64% of the total shares.
The Vanguard Group, Inc. holds 1.27M shares, accounting for 5.71% of the total shares.
Meridian Venture Partners holds 1.01M shares, accounting for 4.55% of the total shares.
State Street Investment Management (US) holds 716.12K shares, accounting for 3.21% of the total shares.
Esjay L.L.C, holds 632.62K shares, accounting for 2.84% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.37M shares, accounting for 10.64% of the total shares.
The Vanguard Group, Inc. holds 1.27M shares, accounting for 5.71% of the total shares.
Meridian Venture Partners holds 1.01M shares, accounting for 4.55% of the total shares.
State Street Investment Management (US) holds 716.12K shares, accounting for 3.21% of the total shares.
Esjay L.L.C, holds 632.62K shares, accounting for 2.84% of the total shares.
What are the top three shareholder types of ANI Pharmaceuticals Inc?
The top three shareholder types of ANI Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
How many institutions hold shares of ANI Pharmaceuticals Inc (ANIP)?
As of 2025Q4, 507 institutions hold shares of ANI Pharmaceuticals Inc, with a combined market value of approximately 21.97M, accounting for 100.49% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.78%.
What is the biggest source of revenue for ANI Pharmaceuticals Inc?
In FY2025Q2, the Sales of generic pharmaceutical products business generated the highest revenue for ANI Pharmaceuticals Inc, amounting to 90.30M and accounting for --% of total revenue.
